سعر رازيروكسبين 250مجم 28 اقراص 2022

Deferasirox 250 mg dispersible tablets (oral iron chelator), pack of 28 (4 strips).

• Chronic iron overload due to blood transfusions in patients 2 years of age and olderDailyMed (U.S. National Library of Medicine)
• Chronic iron overload in patients 10 years and older with non-transfusion-dependent thalassaemia syndromes (with elevated liver iron concentration)DailyMed (U.S. National Library of Medicine)

• eGFR < 40 mL/min/1.73 m2; poor performance status; high-risk myelodysplastic syndromes; advanced malignancies; platelet counts < 50 x 10^9/L; known hypersensitivity to deferasirox.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Boxed warning: may cause acute renal failure (sometimes fatal), hepatic failure and gastrointestinal haemorrhage, particularly in patients with comorbidities or advanced haematologic disease.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Aluminium-containing antacidsDo not take together with deferasirox.DailyMed (U.S. National Library of Medicine)
• Repaglinide (CYP2C8 substrate)Deferasirox increases exposure; consider repaglinide dose reduction and monitor glucose.DailyMed (U.S. National Library of Medicine)
• Theophylline (CYP1A2 substrate)Avoid concomitant use.DailyMed (U.S. National Library of Medicine)

• No studies in pregnant women; in rats, decreased offspring viability and renal anomalies in male offspring at doses about or below the human dose.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• No human data on presence in milk; deferasirox is excreted in rat milk; because of potential serious adverse reactions in the breastfed child, decide whether to discontinue breastfeeding or the drug.International label, same formulation · DailyMed (U.S. National Library of Medicine)